RxDoctor Payments Data

Kevin McDonald, MD

Urology · Hays, KSNPI 1548362866

Payments from drug & device makers

$1,741in general payments, 2019–2025

Across 70 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$494
  • Boston Scientific$202
  • Astellas Pharma US Inc$197
  • Johnson & Johnson$194
  • Medtronic$155
  • AbbVie$145
  • plus $355 from 14 others

What the payments were for

  • Travel & lodging$292%
  • Food & beverage$1,71198%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Procept Biorobotics Corporation7$494
Boston Scientific5$202
Astellas Pharma US Inc15$197
Johnson & Johnson8$194
Medtronic(2 entities)4$155
AbbVie(2 entities)9$145
Axonics, Inc.2$55
Tolmar Pharmaceuticals, Inc.3$51
Coloplast2$33
Pfizer2$28
Alnylam Pharmaceuticals Inc.2$27
Progenics Pharmaceuticals, Inc.1$26
Myovant Sciences Inc.2$26
Travere Therapeutics, Inc.2$24
180 Medical, Inc.1$20
Civco Medical Instruments1$17
Neotract Inc.1$17
Rochester Medical Corporation1$16
Merck1$12
Genentech USA, Inc.1$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,741 in reported general payments places this provider in the 35th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$49,747
Medicare patients
217
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron24$10,503
NitrofurantoinNitrofurantoin Macrocrystal15$1,462
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$804
Tamsulosin Hcl54$791
Oxybutynin Chloride44$755
Solifenacin Succinate13$378
Oxybutynin Chloride ErOxybutynin Chloride12$197
Finasteride12$72
Ciprofloxacin Hcl11$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$197$10,50324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 111 urology providers in Kansas.

Other urology in Hays

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →